AKUMS
DRUGS & PHARMACEUTICALS LTD.
Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, (Adjoining CBSE Office) Delhi - 110083 (INDIA).
+91-11-69041000 CIN: L24239DL2004PLC125888
www.akums.in
akumsho@akums.net
+91-11-27023256

Ref: Akums/Exchange/2026-27/34

July 23, 2026

To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Symbol: AKUMS

To,
The Listing Department
BSE Limited
25th Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy
Towers, Dalal Street, Mumbai – 400 001

Scrip Code: 544222

Sub: **Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition of Oriflame India's Manufacturing business**

Respected Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that **Pure and Cure Healthcare Private Limited**, a wholly-owned subsidiary of **Akums Drugs and Pharmaceuticals Limited ("the Company")** at its Board Meeting held today, i.e. 23rd July, 2026 has, inter alia, considered and approved acquisition of Oriflame India Private Limited's manufacturing business for total consideration of INR 56 Crore. It includes two manufacturing plants at Roorkee, Uttarakhand and Noida, Uttar Pradesh, along with a leased warehouse situated at Noida.

Cosmetics is a fast-growing opportunity in India and this will mark as Akums' entry into color cosmetics; and expand its presence in skincare & wellness products as well. The trademark and marketing of Oriflame's products in India is not part of this transaction.

The details required to be furnished under Regulation 30 of SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is annexed as **"Annexure-A"**.

The above intimation was received by the Company today at 05:56 P.M. (IST)

You are requested to kindly take the above information on your records.

Thanking You
Yours Faithfully

For **Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik
Digitally signed by Dharamvir Malik
Date: 2026.07.23 23:10:23 +05'30'

Dharamvir Malik
Company Secretary & Compliance Officer

Encl.: As above

Annexure-A

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular vide No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sr. No.	Particular	Details
a.	Name of the target entity, details in brief such as size, turnover etc.	Not applicable as no entity is being acquired. Further, Oriflame India Private Limited is in the business of manufacturing and marketing of cosmetic and wellness products.
b.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
c.	Industry to which the entity being acquired belongs	Not Applicable, as no entity is being acquired.
d.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The object is to acquire the manufacturing business of Oriflame India Private Limited situated at two locations i.e. Roorkee, Uttarakhand and Noida, Uttar Pradesh, along with a leased warehouse situated at Noida. This will expand Akums' manufacturing capacity as well as capability of cosmetic and wellness products for Indian as well as global markets.
e.	Brief details of any governmental or regulatory approvals required for the acquisition	No prior governmental or regulatory approvals are required to be obtained for the said transaction.
f.	Indicative time period for completion of the acquisition	Acquisition is expected to be completed by 31st August 2026
g.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration
h.	Cost of acquisition and/or the price at which the facilities are acquired	For a total consideration of INR 56 Crores
i.	Percentage of shareholding / control acquired and / or number of shares acquired	Not applicable
j.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not applicable